Compare LPTH & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | PHAR |
|---|---|---|
| Founded | 1985 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2011 | 2020 |
| Metric | LPTH | PHAR |
|---|---|---|
| Price | $10.10 | $11.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $13.33 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 3.3M | 20.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,202,630.00 | N/A |
| Revenue This Year | $83.04 | $10.04 |
| Revenue Next Year | $24.83 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $5.75 | $9.62 |
| 52 Week High | $18.94 | $21.34 |
| Indicator | LPTH | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 41.53 | 42.27 |
| Support Level | $9.60 | $11.03 |
| Resistance Level | $13.21 | $13.51 |
| Average True Range (ATR) | 0.89 | 0.35 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 21.85 | 4.72 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.